What are the adverse reactions of entrectinib?

Entrectinib (Entrectinib) is a targeted therapy drug that is usually used to treat patients with tumors carrying NTRK gene fusion or ROS1 ROS1 gene rearrangement. Although entrectinib is considered a relatively well-tolerated drug, some adverse reactions may still occur during treatment. The severity and incidence of these adverse reactions may vary between individuals. The following are common entrectinib adverse reactions:

1.Adverse reactions in the digestive system:

Nausea and Vomiting: During treatment with entrectinib, patients may experience mild to moderate nausea and vomiting, which may affect the patient's appetite and quality of life.

Diarrhea: Diarrhea is another common adverse effect that may lead to dehydration and electrolyte imbalance. Doctors may advise patients to maintain adequate fluid intake and manage it appropriately.

2.Nervous system adverse reactions:

Headache: Headache is one of the common adverse reactions during entrectinib treatment. It is usually mild to moderate, but in some cases medication may be needed to relieve symptoms.

Fatigue: Fatigue is also a common adverse reaction, which may affect patients' daily life and activities. Rest and moderate exercise may help relieve this symptom.

3.Adverse reactions to skin and appendages:

Skin rash: During treatment with entrectinib, patients may experience skin reactions such as rash or itching. These reactions are usually mild, but may sometimes require intervention and treatment from a doctor.

Alopecia: Some patients may experience hair thinning or hair loss, which may have a negative impact on the patient's mental and emotional state.

4.Visual adverse reactions:

Blurred vision: Some patients may experience blurred vision or other visual disturbances during treatment with entrectinib. This may affect their daily activities and safety, so the doctor needs to be informed promptly.

5.Adverse reactions of cardiovascular system:

Hypertension: Treatment with entrectinib may cause patients to develop hypertension, which may require monitoring and management. During the treatment process, the doctor may recommend that the patient regularly measure blood pressure and adjust the treatment plan.

Arrhythmias: In rare cases, entrectinib treatment may induce cardiac arrhythmias, which may require ECG monitoring and appropriate management.

6.Other adverse reactions:

Abnormal liver function: Entrectinib treatment may cause abnormal liver function, such as elevated transaminases. Your doctor may recommend regular monitoring of liver function and treatment adjustments as needed.

Myelosuppression: A small number of patients may develop myelosuppression, such as leukopenia or thrombocytopenia, during entrectinib treatment. This may increase the risk of infection and bleeding and therefore requires close monitoring and management.

It is worth noting that not every patient will experience the adverse reactions listed above, and their incidence and severity may vary depending on individual differences and treatment conditions. During the use of entrectinib, patients and doctors should maintain close communication and promptly report any symptoms of discomfort so that the treatment plan can be adjusted in a timely manner and supportive treatment can be provided.